Stocks · News reference
Lexicon Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 12:46 PM
- Checked
- Aug 6, 2026, 12:46 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 800 percent decrease over earnings of $0.01 per share
Read original at benzinga8-K filing — LEXICON PHARMACEUTICALS, INC. (LXRX)
Filed: 2026-08-06 AccNo: 0001062822-26-000112 Size: 236 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar